Table 1.
Effect of cancer treatment on COVID-19 severity in cancer patients
| References | Type of treatment | % Outcomes (M=mortality and SS=severe symptoms) NS: non-significant |
|---|---|---|
| 19 | Immunotherapy | M: 33.33 vs. 5 (no-cancer) and SS: 66.8 vs. 16 (no-cancer) |
| Surgery | M: 25 vs. 5 (no-cancer), and SS: 62.5 vs. 16 (no-cancer) | |
| Chemotherapy | M: 12 vs. 5 (no-cancer), NS and SS: 41 vs. 16 (no-cancer) | |
| Radiotherapy | M: 8 vs. 5 (no-cancer), NS and SS: 23 vs. 16 (no-cancer) NS | |
| 99 | Immunotherapy or target therapy | SS: 81, non-SS: 19 |
| Surgery | SS: 40, non-SS: 60 | |
| Chemotherapy or radiotherapy | SS: 34, non-SS: 66 | |
| 135 | Immunotherapy | SS in lung cancer: 58 vs. 35 (non-immunotherapy treatment) SS in other solid cancers: 26 vs. 15 (non-immunotherapy treatment) |
| Surgery | NS difference in groups (treated vs. not treated with surgery) | |
| Chemotherapy | NS difference in groups (treated vs. not treated with chemotherapy) | |
| 56 | Immunotherapy | M: 33 vs. 27 (no-treatment), NS |
| TKI therapy | M: 29 vs. 27 (no-treatment), NS | |
| Chemotherapy | M: 48 vs. 27(no-treatment) | |
| 194 | Treatments within 4 weeks before symptom onset | |
| Immunotherapy | M: 1 vs. 6 (live), NS | |
| Surgery | M: 3 vs. 0 (live), NS | |
| Chemotherapy | M: 11 vs. 44 (live) | |
| Radiotherapy | M: 4 vs. 9 (live) NS | |
| Target therapy | M: 4 vs. 18 (live) | |
| 195 | Chemotherapy | Patients with haematological malignancies having recent chemotherapy treatment are at higher risk of death during COVID-19-associated hospital admission (OR 2·09, 95% CI 1·09-4·08; p=0·028) |
| 47 | Non-cytotoxic therapies: Immunotherapy, radiotherapy, target therapy and endocrine therapy | Treated vs not treated within 4 weeks of COVID-19 diagnosis M: 11 vs. 14, NS SS: 24 vs. 28, NS |
| Surgery: | Treated vs not treated within 4 weeks of COVID-19 diagnosis M: 19 vs. 13, NS and SS: 38 vs. 26, NS |
|
| Chemotherapy | Treated vs not treated within 4 weeks of COVID-19 diagnosis M: 14 vs. 14, NS and SS: 22 vs. 28, NS |
|
| 196 | Immunotherapy, Surgery, Chemotherapy, Radiotherapy, Hormone therapy and Target therapy | No significant effect on mortality for patients who had the therapies in the past 4 weeks compared to non-treated patients |
| 55 | Immunotherapy (anti-PD-1), Chemotherapy and TKI therapy | No significant difference in M and SS vs. non-treated patients with respective therapy |